Lars Johansson, Chief Scientific Officer at Antaros Medical, will be discussing non-invasive imaging of fibrogenesis and fibrosis at the 2nd Extracellular Matrix Pharmacology Congress next week. His talk will form part of the Quantifying Fibrosis Symposium and will cover how imaging methods like magnetic resonance (MRI) and positron emission tomography (PET) can be applied to understand fibrosis.
With fibrosis being the common end stage in many diseases and organs, and as effective treatment options for fibrotic disease are lacking, the research activity in this field is high. New, effective pharmacotherapies are needed to improve the outcome of patients affected by fibrotic disease. Moreover, current methods to assess fibrosis are either invasive or not sensitive enough to detect early fibrosis, fibrogenesis, and fibrolysis. There is therefore a need to develop non-invasive methods to detect, stage, and study the molecular processes that drive the pathology of fibrosis and enable assessment of treatment effects in the search for novel antifibrotic drugs.
To hear more, catch Lars’ talk on Monday 17 June @ 16:05 CEST. The ECM Pharmacology Congress takes place from 17-19 June in Copenhagen, Denmark. Find the whole programme here.